Industry insights and figures Manufacture of basic pharmaceutical products and pharmaceutical preparations

Operating margin
22.9 %
2019
Companies
4000
2020

Key insights Manufacture of basic pharmaceutical products and pharmaceutical preparations

Actionable signals from current data
EU27_2020
Average operating result: 22.9% of revenue (2019).
Personnel costs: 14.0% of revenue (2019).
Number of companies: 4,000 (2020).

Sector outlook Manufacture of basic pharmaceutical products and pharmaceutical preparations

Automated analytical commentary based on the most recent Eurostat figures

Industry overview

The Manufacture of basic pharmaceutical products and pharmaceutical preparations sector across EU27 average comprises approximately 4,088 enterprises employing about 535,888 people and generating €333.8 bn in net turnover in 2019. The average enterprise size is – employees per firm. This is a useful yardstick when assessing whether your own operation sits within the typical scale band of the sector.

Profitability

With a robust operating margin of 22.9% of revenue in 2019, the sector reports €76.5 bn of gross operating surplus (Eurostat's EBITDA-equivalent, before depreciation). This figure provides the headline benchmark against which an individual operator can sanity-check their own bottom line, values significantly below indicate cost or pricing pressure, those above suggest competitive advantage worth defending.

Cost structure

The Manufacture of basic pharmaceutical products and pharmaceutical preparations cost mix is reasonably balanced: cost of revenue at 66.9%, personnel at 14.0% and energy at – of turnover. Without a single dominant cost driver, margin management requires attention across the full operating envelope rather than focus on any one line.

Trend & trajectory

Over the period 2011 to 2019 the operating margin moved from 21.1% to 22.9% (+1.8 percentage points), an encouraging upward trajectory. Sectors with stable or improving margins tend to reflect successful pass-through of input costs and disciplined capacity management; declining margins typically point to either over-supply or a structural cost squeeze that warrants strategic review.

Costs by category Manufacture of basic pharmaceutical products and pharmaceutical preparations

Sector average % of revenue
Log in to see the full 8-year history
Cost structure for Manufacture of basic pharmaceutical products and pharmaceutical preparations in EU27_2020, 2011 to 2019, expressed as percentage of revenue.
Revenue / costs 2011 2012 2013 2014 2015 2016 2017 2019
Total revenue 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Personnel costs (total) 14.2% 14.6% 14.6% 14.8% 13.9% 13.9% 13.9% 14.0%
Gross wages 10.8% 11.2% 11.2% 11.3% 10.5% 10.7% 10.6% 10.8%
Social and pension contributions 3.4% 3.4% 3.4% 3.6% 3.4% 3.2% 3.3% 3.1%
Other costs 64.7% 64.1% 65.6% 66.2% 66.7% 63.8% 63.3% 63.1%
Gross operating surplus (EBITDA) 21.1% 21.3% 19.7% 19.0% 19.4% 22.3% 22.7% 22.9%

Source: Eurostat Structural Business Statistics (latest available year).

Operating result over 8 years

Sector average % of revenue
Average
21.1%
Peak
22.91%
2019
Low
19.02%
2014
Latest
22.91%
2019

Cost mix evolution

How costs have shifted as a share of revenue

Cost distribution as % of revenue Manufacture of basic pharmaceutical products and pharmaceutical preparations (2019)

Recommended next steps

Based on the latest available data for Manufacture of basic pharmaceutical products and pharmaceutical preparations